Tranzactioneaza Bristol-Myers Squibb Company (US.BMY) - 55.88 USD (%) Tranzactioneaza

LPO (US.BMY) Bristol-Myers Squibb va achizitiona Mirati Therapeutics

Bristol-Myers Squibb, una dintre cele mai mari companii farmaceutice din lume, a anuntat achizitia producatorului de medicamente oncologice, Mirati Therapeutics. In acest sens, Bristol-Myers a acceptat sa plateasca 4.8 mld. USD pentru aceasta achizitie, adica 58 USD/actiune, ceea ce semnifica o prima de 52% fata de valoarea medie ponderata a pretului din ultimele 30 de zile de tranzactionare. (Sursa: news)

Bristol Myers Sues AstraZeneca Over PD-L1 Cancer Drug Patents

Bristol Myers Squibb Co (US.BMY) claims that AstraZeneca (US.AZN) PD-L1 inhibitor, Imfinzi, infringed on at least eight patents in a newly filed complaint. The lawsuit in Delaware federal court said that the use of Imfinzi to treat lung and bladder cancer infringes several patents on Bristol's immunotherapy Opdivo.&nbsp

From the complaint: AstraZeneca exploits Plaintiffs' inventions and infringes Plaintiffs' intellectual property rights by marketing a later-developed anti-PD-L1 antibody product, Imfinzi (durvalumab), used in methods for treating cancer and for enhancing the immune response.

bristol myers sues astrazeneca over 04179 1727